Navigation Links
Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
Date:11/9/2011

TAMPA, Fla. -- A protein called "fascin" appears to play a critical transformation role in TGF beta mediated tumor metastasis, say researchers at Moffitt Cancer Center in Tampa, Fla., who published a study in a recent issue of the Journal of Biological Chemistry.

According to study corresponding author Shengyu Yang, Ph.D., of Moffitt's Comprehensive Melanoma Research Center and the Department of Tumor Biology, elevated Transforming Growth Factor beta in the tumor microenvironment may be responsible for fascin over-expression, which in turn can promote metastasis in some metastatic tumors.

TGF beta is a versatile cytokine involved in many physiological and pathological processes in adults and in the developing embryo, including cell growth, cell differentiation, cell death (apoptosis) and cellular homeostasis. TGF beta is best known as a tumor suppressor, exerting growth inhibitory roles in normal tissue and early stage tumors. However, many metastatic tumors are able to overcome the growth inhibition and secreted elevated levels of TGF beta to promote tumor metastasis. How TGF beta promotes metastasis is not completely understood. The authors suggested that fascin may be the key to understand the pro-metastasis function of TGF beta, as fascin knockdown almost completely abolished TGF beta induced tumor cell migration and invasion.

The researchers explained that fascin levels are low or not detected in normal tissues, but are highly elevated in malignant tumors. Also, high fascin expression is associated with poor prognosis. It has been clear for some time, they noted, that there is a causal role for fascin over-expression in tumor cell dissemination. However, the underlying mechanism for the elevation of fascin levels has not been clarified. Their analysis using cell culture- based assay and patient microarray data mining strongly suggests that elevated TGF beta levels in tumors lead to fascin overexpression, which in turn promotes metastasis.

"Our data suggests that fascin is an immediate TGF beta target gene essential for its pro-invasion activity in cancer metastasis," explained Yang.

While there have been many studies on the role of fascin in tumor cell migration and metastasis, the current study is first to report that TGF beta elevates fascin protein expression to promote invasion, particularly in tumor cells of spindle-shaped the kind of morphology associated with high tumor invasiveness and more metastatic disease.

"The finding that TGF beta only induces fascin over-expression in highly metastatic tumor cells is especially interesting," said Yang. "Therapies targeting fascin may block TGF beta mediated metastasis without interfering with the tumor suppressor role of TGF beta in normal tissues."


'/>"/>
Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
3. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
4. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
5. Moffitt Cancer Center researchers find more clues to causes of breast cancer
6. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
7. Enhancing arrest of cell growth to treat cancer in mice
8. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
9. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
10. Low forms of cyclin E reduce breast cancer drugs effectiveness
11. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home ... of Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business ... our agency and our ability to provide quality care to the community,” said Tammara ...
(Date:4/21/2017)... ... April 21, 2017 , ... Each year, everyone is ... day to clean, plant trees and look forward to a better future. However, supporting ... doing something outdoors. Indoor air quality can be two to five times more polluted ...
(Date:4/21/2017)... ... April 21, 2017 , ... A ... for older shoulder replacement patients; post-operative recovery just might be even better than ... patients presenting with osteoarthritis following surgery: 262 patients under 65 and 103 patients ...
(Date:4/21/2017)... NC (PRWEB) , ... April 21, 2017 , ... ... non-profit a $5 million grant over five years to help end the disability ... ambitious 15-year plan in cooperation with the Global Clubfoot Initiative to end disability ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology: